Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Arsanis Biosciences Gmbh

Eveliqure Biotechnologies Gmbh

Valeria Szijárto

Eszter Nagy

Gábor Nagy

Adriana Badarau

Irina Mirkina

Luis Guachalla

Hedda Wardemann

Tamás Henics

Maximiliano Vasquez

Katharina Ramoni

Tim Rollenske

A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

O3 specific antibodies

A live attenuatedvaccine, which is based on a roughstrain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and astrain, which is a2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutatedinvasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.

Live attenuated Shigella vaccine

Growing community of inventors

Vienna, Austria

Valeria Szijárto